BioCentury | Oct 15, 2020
Product Development

Lingering questions as Vertex sheds $15B after Phase II setback

...the stellar launch of Vertex’s flagship Trikafta elexacaftor/tezacaftor/ivacaftor...
BioCentury | Oct 7, 2020

Roche deal for CF program brings return to Enterprise’s syndicate without full takeout

...transformed the CF treatment landscape in recent years. Those, including Kalydeco ivacaftor, Orkambi ivacaftor/lumacaftor and Trikafta elexacaftor/tezacaftor/ivacaftor...
BioCentury | Aug 25, 2020

Reverse merger offers Yumanity faster, less risky path to NASDAQ

...did not measure up to Vertex’s Trikafta elexacaftor/tezacaftor/ivacaftor...
BioCentury | Jul 24, 2020
Product Development

July 23 Quick Takes: Priority Review for Aurinia; plus Jazz, CymaBay, Biogen, Vertex, Grünenthal, Mesoblast, BMS and Genfit

...CF combo meets in postapproval study Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said cystic fibrosis therapy Trikafta elexacaftor/tezacaftor/ivacaftor...
...vanilloid 1 BioCentury Staff voclosporin (LX211, luveniq, ISA247, ISATX247, trans-ISA247, Voclera) JZP-258 Qutenza, capsaicin (NGX-4010, Transacin) Ryoncil (remestemcel-L) elafibranor (GFT505) Trikafta, elexacaftor/tezacaftor/ivacaftor (VX-445/VX-661/VX-770) liso-cel...
BioCentury | Jul 10, 2020

How buysiders are sizing up commercial launches during the pandemic

...very cheaply.” David Borah, GW&K An example is the cystic fibrosis (CF) combination therapy Trikafta elexacaftor/tezacaftor/ivacaftor...
BioCentury | Jun 30, 2020
Product Development

Vertex, NHS in deal to make CF triplet available in England once EC approves

...Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) and NHS that had provided access to Orkambi lumacaftor/ivacaftor and Symkevi tezacaftor/ivacaftor...
...England. Under the new arrangement, CF patients in England will have immediate access to Kaftrio elexacaftor/tezacaftor/ivacaftor...
...Trials Landscape” ). Targets CFTR - Cystic fibrosis transmembrane conductance regulator Stephen Hansen, Associate Editor Trikafta, elexacaftor/tezacaftor/ivacaftor (VX-445/VX-661/VX-770) Vertex...
BioCentury | Jun 26, 2020

Data Bytes: CHMP’s June opinions

...certain adults with transfusion-dependent anemia. Elizabeth S. Eaton, Staff Writer Veklury, remdesivir (GS-5734) Reblozyl, luspatercept-aamt (ACE-536) IdeS, imlifidase Trikafta, elexacaftor/tezacaftor/ivacaftor (VX-445/VX-661/VX-770) Turalio...
BioCentury | May 25, 2020

New additions to the IPO queue: Generation Bio, Avidity, Vaxcyte and more

...from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), which includes Kalydeco ivacaftor, Orkambi ivacaftor/lumacaftor, Symdeko tezacaftor/ivacaftor and Trikafta elexacaftor/tezacaftor/ivacaftor...
BioCentury | Apr 30, 2020

April 29 Quick Takes: After ADC approval, Immunomedics raises $420M for rollout; plus Genespire, Vertex, Ocumension and Cadent

...billion, after the company reported a year-over-year sales increase of 77%. Cystic fibrosis therapy Trikafta elexacaftor/tezacaftor/ivacaftor...
BioCentury | Apr 4, 2020

Investors are seeking only one thing: a sign the pandemic tide is shifting

...instance, Craig said there’s little worry about the launch of new cystic fibrosis therapy Trikafta elexacaftor/tezacaftor/ivacaftor...
Items per page:
1 - 10 of 157